Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Tirzepatide, the active ingredient in Mounjaro, remains under investigation for pregnancy safety and is not approved for use during gestation. Current clinical guidelines recommend discontinuing tirzepatide at least three months before attempting pregnancy, though individual circumstances vary based on medical history and weight loss goals.
Is Tirzepatide Safe During Pregnancy?
Tirzepatide has not been adequately studied in pregnant women, making its safety profile during pregnancy unknown. Animal reproduction studies in mice and rats showed dose-dependent embryo-fetal toxicity at exposures well above typical human therapeutic doses, raising concerns about potential risks to developing fetuses. The U.S. Food and Drug Administration classifies tirzepatide as a Category C medication for pregnancy, meaning risk cannot be ruled out but human data remains limited.
No randomized controlled trials have evaluated tirzepatide use in pregnant patients, so medical professionals cannot confidently predict how the medication might affect fetal development, placental function, or maternal metabolic changes during pregnancy. Because pregnancy itself significantly alters how the body processes medications, the pharmacokinetics of tirzepatide during gestation remain entirely theoretical. For these reasons, tirzepatide is considered contraindicated—meaning actively not recommended—during pregnancy.
What Do Medical Guidelines Say About GLP-1 Therapy and Pregnancy?
The American College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA) both recommend that women using GLP-1 receptor agonists stop treatment before conception. Current guidance suggests discontinuing tirzepatide at least three months before attempting to become pregnant, allowing adequate time for the medication to clear from the body and for metabolic adaptation to occur. This washout period helps ensure that early fetal development occurs without active GLP-1 pathway stimulation.
Healthcare providers typically counsel women on tirzepatide therapy to use reliable contraception to prevent unintended pregnancy and to notify their doctor immediately if they become pregnant while on treatment. Some physicians recommend weight loss milestones be achieved before conception planning, reducing the need for continued pharmacotherapy during pregnancy. Individual risk-benefit discussions are essential, as severe obesity in pregnancy carries its own significant maternal and fetal complications.
What Happens to Weight Loss After Stopping Tirzepatide Before Pregnancy?
Women who discontinue tirzepatide to prepare for pregnancy often experience weight regain within weeks to months after stopping the medication. Studies show that GLP-1 effects on appetite and metabolism reverse relatively quickly once the drug is removed from circulation, meaning hunger signals and caloric intake typically increase back toward baseline. The degree of weight regain varies based on dietary habits, physical activity, baseline metabolism, and how long the medication was used.
Healthcare providers may recommend lifestyle modifications, structured nutrition counseling, and supervised exercise programs during the pre-conception months after stopping tirzepatide to minimize rebound weight gain. Some women achieve partial weight stability through behavioral changes alone, while others experience significant regain. Pregnancy itself adds metabolic demands and weight gain that are medically appropriate, making pre-pregnancy weight optimization a reasonable clinical goal.
Can You Resume Tirzepatide After Pregnancy and Breastfeeding?
Tirzepatide is not recommended during breastfeeding because it passes into breast milk in animal studies, and human lactation data do not exist. Women who breastfeed are advised to wait until nursing is complete before resuming tirzepatide therapy, though some providers may discuss individual timelines based on infant feeding plans. If a woman plans to breastfeed exclusively for six months or longer, resuming GLP-1 therapy may be delayed significantly postpartum.
After weaning is complete and the postpartum period has progressed (typically at least six weeks postpartum, longer if complications occurred), women may restart tirzepatide under medical supervision. The restart dosing protocol typically begins at the lowest dose and titrates gradually, similar to initial treatment, because medication sensitivity may have changed during pregnancy and postpartum metabolic shifts. PlexusDx providers can reassess individual factors and coordinate a safe re-introduction plan once breastfeeding has ended.
How PlexusDx Supports Pregnancy Planning on GLP-1 Therapy
Women using PlexusDx compounded tirzepatide who are planning pregnancy receive personalized guidance on medication discontinuation timing and transition planning. PlexusDx operates in all 50 states and works with patients to coordinate care with their obstetrician or primary care provider, ensuring that pregnancy preparation aligns with both weight management goals and fetal safety. The Precision Peptide Genetic Test can identify individual peptide-pathway sensitivities, helping inform whether alternative post-pregnancy weight management strategies might be beneficial.
PlexusDx tirzepatide injection starts at $249 per month with no flat per-compound pricing increases—meaning medication costs remain predictable as your provider adjusts your therapeutic dose. If you are considering pregnancy or currently pregnant, contact your PlexusDx provider immediately to discuss stopping tirzepatide, timing of discontinuation, and post-pregnancy resumption options. HSA and FSA accounts are accepted, helping offset the costs of medically supervised weight management and genetic testing for personalized peptide insights.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What should I do if I become pregnant while taking tirzepatide?
Stop tirzepatide immediately and contact your obstetrician and your PlexusDx provider right away. Pregnancy was not studied in tirzepatide trials, so your healthcare team will want to monitor you and your baby closely throughout pregnancy to watch for any unexpected changes.
How long after stopping tirzepatide can I try to conceive?
Most medical guidelines recommend waiting at least three months after your last tirzepatide dose before attempting pregnancy, allowing the medication to fully clear your system and your metabolism to re-stabilize. Your individual timeline may differ based on your medical history and provider recommendations.
Will I regain weight after stopping tirzepatide for pregnancy?
Weight regain is common after discontinuing GLP-1 medications because appetite and metabolism return to baseline fairly quickly. Working with a nutritionist and maintaining physical activity during this transition can help minimize rebound weight gain, though some weight gain typically does occur.
Can I use tirzepatide while breastfeeding?
No, tirzepatide passes into breast milk in animal models and is not recommended during breastfeeding. You should wait until breastfeeding is complete before restarting tirzepatide, typically at least six months postpartum depending on your feeding plan.
Does the PlexusDx Precision Peptide Genetic Test help predict how I'll respond after stopping and restarting tirzepatide?
The Precision Peptide Genetic Test ($99 add-on) maps 14 metabolic pathways and identifies genetic variants in GLP-1 receptor sensitivity and appetite regulation, offering insights into individual peptide responsiveness. This personalized data can inform whether alternative weight management approaches during pregnancy planning might be beneficial for your unique genetic profile.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Where to Get Ozempic for Weight Loss: A Professional Breakdown
How to Reduce Nauseea on Zepbound: Effective Strategies for Comfort